MABXIENCE RESEARCH SL.
Location
Madrid
Founded
2015-12-23
Website
Risk Signals
16 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MABXIENCE RESEARCH SL.
Live alerts from global media, monitored by Business Radar
2024-02-07 (contractpharma.com)
mAbxience and Biosidus Enter CDMO Agreement |
mAbxience will manufacture the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme for the treatment of Fabry disease.
Read more
2023-12-25 (indiatimes.com)
Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience
Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of America.
Read more